Catequentinib
Diffuse Large B Cell Lymphoma Refractory
Zhejiang Cancer HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the Diffuse Large B Cell Lymphoma Refractory cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rondecabtagene Autoleucel Lyell Immunopharma, Inc. | Phase 3 | B |
ezm0414 Epizyme, Inc. | Phase 1 | CC |
vk-2019 Pierluigi Porcu | Phase 1 | CC |
Vancomycin Abramson Cancer Center at Penn Medicine | Phase 1 | CC |
Same molecule, other indications
Catequentinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →